Primary Treatments for Intermediate-Risk Prostate Cancer: A Cost-Effectiveness and Value-Of-Information Analysis

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.566
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost Effectiveness of Prostate Boost With High-Dose Rate Brachytherapy Versus Intensity Modulated Radiation Therapy in the Treatment of Intermediate-High Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Expending the Paradigm: Active Surveillance for Intermediate Risk Prostate Cancer

Open Journal of Urology
2018English

Ultrahypofractionation Should Be a Standard of Care Option for Intermediate-Risk Prostate Cancer

Clinical Oncology
Nuclear MedicineRadiologyImagingOncology
2020English

Pcn153 - Cost-Effectiveness Analysis of Apalutamide for Treatment in Non- Metastasis Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Mp18-07 Applicability Analysis of Focal Therapy to Intermediate- And High-Risk Prostate Cancer

Journal of Urology
Urology
2016English

Cost-Effectiveness Analyses and Cost Analyses in Castration-Resistant Prostate Cancer: A Systematic Review

PLoS ONE
Multidisciplinary
2018English

Cost, Effectiveness, and Value

JAMA - Journal of the American Medical Association
Medicine
2016English

Cost-Effectiveness Analysis of End-Stage Renal Disease Treatments

Medical Care
EnvironmentalPublic HealthOccupational Health
1987English

Radon and Lung Cancer: A Cost-Effectiveness Analysis.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy